MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corporation (“MedX” or the “Company”) (TSX-V: MDX) and Empower Clinics Inc. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) ("Empower" or the "Company") are pleased to announce a Memorandum of Understanding between the companies to pilot MedX’s leading-edge DermSecure™ Screening Platform at two select Empower Clinics in Ontario with plans for a broader market roll-out pending the pilot’s completion.
“Empower exists to make testing, screening and diagnostics as convenient as possible for patients,” said Steven McAuley, Chairman and CEO of Empower. “Providing our patients with easy access to quality virtual services like teledermatology compliments our current COVID-19 testing solutions amid the ongoing pandemic. MedX is an ideal teledermatology partner, as their screening platform is second to none. We look forward to the results of this pilot and making this platform more widely available throughout our network.”
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care – patient screening, assessment and diagnosis – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s DermSecure™ Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
“With only about 500 dermatologists available to serve over 37 million Canadians, the wait times to see a specialist in-person can be anywhere from five months to one year,” said Mike Druhan, President, Dermatology Services, MedX Health Corp. “The COVID-19 pandemic has nearly doubled the average wait period. We know that early detection of melanoma greatly increases the patient’s survival rate and reduces the cost to the health-care system. Partnering with Empower allows us to dramatically grow our patient base, and ultimately save more lives.”
According to the Canadian Dermatology Association, last year an estimated 8,000 Canadians were diagnosed with melanoma skin cancer and approximately 1,300 Canadians died of the disease. With mortality rates increasing by as much as 1.2% per year since 1984, early and rapid detection is key to improving patient outcomes.
The pilot program will be in place for four months, reaching an estimated 13,500 patients. Pending the pilot’s successful completion, the MedX DermSecure™ Screening Platform will become more widely available at Empower Clinics across North America.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com
About Empower Clinics:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.